Mode
Text Size
Log in / Sign up

Metachronous pancreatic metastasis from ovarian cancer is rare, mostly high-grade serousOvarian cancer can spread to pancreas, rare review finds

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider metachronous pancreatic metastasis in ovarian cancer patients, especially with high-grade serous histology, but evidence is limited.

This systematic review synthesized 8 cases from 7 studies of patients with histologically proven ovarian cancer metastasis to the pancreas. The review focused on metachronous pancreatic metastases from high-grade serous ovarian carcinoma, examining clinical presentations, treatment options, and radiological and histological outcomes.

Most metastases originated from a primary high-grade serous carcinoma. Treatment options included surgical excision and chemotherapy. The review did not report pooled effect sizes, p-values, or confidence intervals, reflecting the descriptive nature of the included case reports.

The authors noted the small sample size (8 cases) as a key limitation, and they emphasized that metachronous pancreatic metastasis from ovarian cancer is rare. No data on adverse events, follow-up duration, or funding were reported.

Clinically, this review highlights a rare metastatic pathway that may be considered in patients with ovarian cancer presenting with pancreatic lesions. However, given the limited evidence, management decisions should be individualized and based on multidisciplinary input.

How this fits prior evidence

This systematic review extends prior coverage of ovarian cancer metastasis by describing a rare metastatic site (pancreas) and its histological origin. It complements prior findings on tumor microenvironment and AI-based metastasis prediction (AUC 0.86) by adding a specific clinical scenario, though it does not address systemic therapy outcomes like PARP inhibitors. The rarity of the condition and small sample size contrast with larger datasets in prior coverage.

Ovarian cancer is a tough opponent. It often spreads within the abdomen, but sometimes it takes a surprising path: to the pancreas. A new review of published cases found this happens, but it's rare. The researchers looked at 8 cases from 7 studies, all involving women with ovarian cancer that had spread to the pancreas at a later time, not at first diagnosis.

In most of these cases, the original tumor was a high-grade serous carcinoma, the most common and aggressive type of ovarian cancer. The women had different symptoms, and doctors treated them with surgery or chemotherapy. The review didn't compare treatments or report survival rates, so we can't say which approach works best.

This is a small, early look at an uncommon problem. The review's authors say that understanding this spread could help doctors manage it better, but they need more research. If you or someone you know faces this, talk to your oncology team about the best plan.

For now, this review is a reminder that cancer can be unpredictable. But it also shows that doctors are paying attention to unusual patterns, which is how we learn and improve care.

What this means for you:
Ovarian cancer can spread to the pancreas, but it's rare; treatment may include surgery or chemo.

Common questions

How common is ovarian cancer spreading to the pancreas?

It's rare. The review found only 8 cases from 7 studies. So while it can happen, it's not a common pattern of spread.

What treatments were used for pancreatic metastasis from ovarian cancer?

The review reported that treatment options included surgical excision and chemotherapy. However, it didn't compare these treatments or say which was more effective.

What type of ovarian cancer was most likely to spread to the pancreas?

In most of the 8 cases, the primary tumor was a high-grade serous carcinoma, which is the most common and aggressive type of ovarian cancer.

Is this review enough to guide treatment decisions?

No. The review is based on only 8 cases and doesn't report outcomes like survival. It's too early to draw firm conclusions. Always discuss your specific situation with your doctor.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
BackgroundOvarian cancer, a leading cause of gynecological cancer mortality, rarely metastasizes to the pancreas. This review seeks to consolidate knowledge about metachronous pancreatic metastases from ovarian cancer, emphasizing clinical presentations, diagnostic challenges, treatment options and outcomes.MethodsFollowing PRISMA guidelines, a systematic literature search was conducted in PubMed, EMBASE, and the Cochrane library between 1989 and December 2023. Only studies with histological proof of ovarian cancer metastasis to the pancreas were considered.ResultsWe identified 7 studies that reported a total of 8 cases. Most metastases originated from a primary high-grade serous carcinoma. The treatment options varied and included surgical excision and chemotherapy; we considered both radiological and histological outcomes.ConclusionsAlthough rare, metachronous pancreatic metastases from ovarian cancer pose a unique clinical challenge. Elucidating this possible metastatic pathway may enhance patient outcomes and help identify the most appropriate management.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.